An NADH-dependent enoyl-acyl carrier protein reductase, FabI, catalyzes the final step of bacterial fatty acid biosynthesis, reducing the double bond of trans-2-enoyl-ACP to a single bond forming acyl-ACP. Given its importance in bacterial fatty acid synthesis, FabI has become a recognized drug target. Triclosan, a diphenyl ether, targets the FabI, inhibits its activity, and stops bacterial growth. However, as a consequence of triclosan's popularity, and thus its overuse, bacterial resistance to triclosan has been reported. The mutation G93V in Escherichia coli (E. coli) FabI allows E. coli to resist the action of triclosan. We have identified the equivalent residue of G93 in Francisella tularensis FabI (ftFabI) as A92, and prepared a mutant A92V. E. coli cells, transformed with a plasmid containing the ftFabI-A92V gene, were grown, and the gene was overexpressed. From two growths (6 G of cells), 62 mG of protein, with a histidine tag, at a purity of 85% were obtained. Enzymatic activity was assayed by monitoring the absorbance of NADH at 340 nm. In the presence of triclosan, the wild-type protein was almost completely inhibited after NADH was converted to NAD + in the enzymatic reaction; however the A92V mutant exhibited similar activity with and without triclosan, demonstrating that triclosan resistance may also develop in Francisella tularensis.
Introduction
Francisella tularensis (F. tularensis or ft) is a gramnegative facultative intracellular bacterium and causes Tularemia in infected hosts. Many cell types can be infected by F. tularensis, yet infection most commonly occurs in macrophages. F. tularensis has a very low infectious dose and can be potentially life threatening without proper treatment. Thus, F. tularensis is categorized by the United States Centers for Disease Control as a "Category A Bioterrorism Agent".
1 It was even developed as a standardized biological weapon in the United States biological weapons program.
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F. tularensis synthesizes its fatty acids with the FASII pathway, which differs from the eukaryotic pathway, FASI, used by humans. 3 The FASII pathway uses several small proteins, each individually coded by discrete genes, while the FASI pathway utilizes a single large protein. Thus, enzymes in the FASII pathway are potential antibacterial drug targets. 4 One of these enzymes, FabI, catalyzes the final step in the FASII pathway in many bacteria to reduce trans-2-enoyl-ACP to acyl-ACP. 5 The commonly used antimicrobial agent triclosan used, for example, in many hand soaps, has been found to inhibit the FabI enzyme. After NADH is converted to NAD + , triclosan and NAD + bind to the enoyl substrate site with high affinity to stop FabI from further acting on its substrate, enoyl-CoA. 6 Triclosan resistant mutations in E. coli and a few other bacterial species have been reported. 7 This is a particular concern as triclosan resistance has been noted to cause cross-resistance to other antibiotics. 8 One such mutation, G93V, in E. coli was found to exhibit resistance to triclosan, with a 95-fold increase in the minimum required inhibitory concentration of triclosan as compared to the wild-type. 9 Due to the structural similarities between E.
coli FabI and F. tularensis FabI (ftFabI), 10 a corresponding mutation in F. tularensis may also lead to triclosan resistance. We have carried out studies on the triclosan effect in ftFabI wild-type and a mutant A92V.
Methods

Sequence Alignment
Sequence alignment was carried out with ClustalW2.
11
Structural Analysis
Preliminary structural analysis was carried out using the PyMOL Molecular Graphics System. 12 The 3D structure of ftFabI 12 (PDB code: 3NRC) with bound triclosan and NAD + was examined, noting relative distances between triclosan and the FabI active site residues. Using PyMOL software, a mutation was carried out at residue 92 to replace A with V to give A92V. The specific side chain rotamer used for valine was the one with the highest percentage occurrence in proteins, specifically with 75.8% occurrence in ftFabI.
Protein Preparation BL21+ E. coli cells were transformed with a pET-15b vector containing either the wild-type or the ftFabI-A92V gene and an N-terminal His-Tag (a gift from the Center of Pharmaceutical Biotechnology at the UIC). Cells were grown in Lysogeny Broth (2L) containing ampicillin. When the optical density at 600 nm (OD-600) was between 0.5 -0.7, the cells were induced with 0.5 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) to overexpress the gene. Cells were grown until the OD-600 value reached about 1.3 (about 4 more hours), harvested and stored at -20
• C, if not processed immediately. Protein was extracted following standard methods.
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Phosphate buffer (50 mM) at pH 8 with 300 mM NaCl, 10 mM imidazole and 1% Triton-X 100 was used as the lysis buffer. Cells were suspended in the lysis buffer and sonicated. Similar buffers, except with 10 mM, 20 mM and 250 mM imidazole, but without triton, were also prepared and used for column loading, washing and elution, respectively. The sonicated mixture was centrifuged at 34,541 g for 30 minutes, and then the supernatant was loaded onto a Ni-affinity column equilibrated with the loading buffer. Subsequently, washing and elution buffers were used. The washing buffer served to elute non-specific proteins not bound to the resins in the column. The elution buffer served to elute the His-tagged protein (ftFabI) bound to the resin. The protein was collected in time-controlled fractions. The 280 nm absorbance of each fraction was measured and an elution profile was obtained. Fractions with high absorbance readings were combined and dialyzed overnight in a 50 mM Tris buffer at pH 8 with 100 mM NaCl, and 1 mM DTT. The purity of the samples (the wild-type and the mutant A92V ftFabI) was analyzed for purity by 16% polyacrylamide gel electrophoresis (PAGE).
Specific Activity Assay
Enzyme activity was carried out using a plate reader (Model: Victor 3 V; Perkin Elmer) by monitoring NADH absorbance at 340 nm (A 340 ).
14 NADH absorbs at 340 nm, while its oxidized form NAD + does not. The decrease in absorbance over time therefore indicates a change from NADH to NAD + as the reaction proceeds. NADH solution, ftFabI (wild-type or mutant A92V), and assay buffer (50 mM Tris at pH 8 with 100 mM NaCl) were prepared to make the final concentrations of NADH and ftFabI in the reaction mixture 200 µM and 1 µM, respectively. Samples containing 5 µM triclosan dissolved in DMSO (approximately 2 µL triclosan in DMSO per 200 µL to create a 5:1 molar ratio of triclosan to FabI in the reaction mixture) were also prepared. To account for changes in absorbance due to the addition of DMSO, 2 µL DMSO was added into the control (no triclosan). However, it was found that the addition of DMSO had a negligible effect on A 340 . The reaction mixture (98 µL was added to the wells of a 96 well plate and A 340 was monitored over approximately 3 minutes to determine a baseline absorbance reading. 2 µL of 10 mM crotonylCoA (an analog of enoyl-CoA) was added to the reaction mixture. The A 340 values were then measured for 14 minutes.
Specific activity was calculated in enzyme units per mG enzyme. However, since the rate of NAD + generation equals the rate of crotonyl-CoA use, the specific
FIG. 1: Alignment of the protein sequences of E. coli
FabI, residues 1-120, and ftFabI, residues 1-119, indicating the equivalent residue of G93 in E. coli FabI is A92 of ftFabI. Residue 93/92 is indicated with a blue arrow.
activity of ftFabI is calculated using units of NADH instead as shown below:
where A t is the absolute value of change in absorbance per min, V is the assay volume (100 µL), ε is the extinction coefficient of NADH (4660 M −1 cm −1 ), l is the path length, or the depth of the well with 100 µL liquid (0.291 cm), and m is the amount (mG) of enzyme. The unit for specific activity is (µmol NAD/min)/mG FabI.
Results
Sequence Alignment
Sequence alignment indicated A92 in ftFabI corresponds to G93 in E. coli FabI (Figure 1 ). The sequence of E. coli FabI from residue 90 to 96 is HSIGFAP, while the sequence of ftFabI from residue 89 to 95 is HSIAFAP. We have carried out studies on the triclosan effect in ftFabI wild-type and A92V mutant.
Protein Characterization
The elution profile of the affinity column of the over expressed, N-terminal His-tagged wild-type ftFabI fusion protein is shown in Figure 2 .
The protein was observed on a 16% SDS gel. The molecular mass, from sequence, of wild-type ftFabI with the His-Tag is 29,968.5 Da, and for ftFabI-A92V with the His-Tag is 29,996.5 Da. A 30,000 Da standard band (Figure 3 a and b) , Lane 1) was used to identify ftFabI. The intensity of this band represents the purity of the protein in the sample. Both wild-type ftFabI (Figure 3  a) , Lane 3) and ftFabI-A92V fusion proteins (Figure 3b) , Lanes 2 and 3) were obtained at a purity of about 85%.
Activity Assays
Wild-type ftFabI samples with and without triclosan were prepared and run in parallel ( Figure 4) . As the reac- tion proceeded, the specific activity of the sample without triclosan decreased due to limiting substrate concentrations. The specific activity of the sample with triclosan had a very similar initial activity to the sample with no triclosan; however, the specific activity of this sample decreased much more rapidly. This is due to the generation of NAD+, through oxidation of NADH, as the reaction proceeded. This generation of NAD + allowed triclosan to complex with the NAD + which inhibited the enzyme ftFabI (Figure 4) . The specific activities taken at 1 minute intervals of both wild-type samples with and without triclosan are shown in Table I .
The results for ftFabI-A92V are shown in Figure 5 and Table II nm. The first 20 readings (from about 0-3 minutes) were taken with no substrate to generate an absorbance baseline. Substrate was added, and additional 99 measurements were taken.
FIG. 6:
The change in specific activity for wild-type ftFabI and A92V ftFabI, with and without 5 µM triclosan. Each point represents the activity value during that time interval. For example, for time = 3 min, the slope from 3 to 4 min was used to calculate the specific activity for each sample. See Tables I and II. TABLE I: Summary of the wild-type assays, with and without triclosan, including the slope and specific activities for each 1 minute time interval. Both assays showed a decrease in activity through the duration of the assays; however, the decrease was greater in the assay with triclosan. The decrease in activity in the assay without triclosan can be attributed to consumption of NADH. The decrease in activity for the assay with triclosan can be attributed to triclosan inhibition as NAD + gets generated. sample ( Figure 6 ). However, in the presence of five-fold molar excess triclosan, the change in the rate dropped dramatically, and leveled off quickly, suggesting progressive inhibition by triclosan during the initial period, after sufficient amounts of NAD + species appeared. In contrast, the A92V mutant maintains a steady turnover rate throughout the course of the assay, similar in magnitude in both the absence and presence of triclosan, indicating that the A92V mutant catalyzes the oxidation of NADH at 40% of the rate of the wild-type, and it resisted triclosan-NAD + binding by acting at that approximate rate in the presence of triclosan.
In comparison, the wild-type exhibited an initial specific activity of about 0. 
Structural Interpretation
We hypothesize that the resistance mechanism stems from increased steric hindrance from residue Val-92. Triclosan binds the enoyl substrate site at a distance of 3.8 A away from Ala-92 ( Figure 7) . However, for triclosan to be in its binding site with valine as residue 92, it would have to be 2.5Å away from Val-92 (Figure 8) . This is not possible since the sum of the van der Waal radii of the 2-chloro of the 2,4-dichlorophenoxy group of triclosan and the 3-carbon of valine is larger than 2.5Å (approximately 3.6Å), demonstrating that a valine should prevent successful triclosan binding and inhibition.
Conclusion
The ftFabI-A92V mutant showed reduced activity as compared to the ftFabI wild-type. This is probably due to the bulkier valine residue affecting the binding of crotonyl-coA. However, this reduced activity was maintained in the presence of triclosan, allowing the bacterial cells to resist triclosan. These results suggest the potential for growth in the presence of triclosan for a strain of Francisella tularensis harboring the ftFabI-A92V.
Another central implication resulting from this study is the importance of developing new antimicrobials. Through overuse, it is generally known that microbes harboring resistant mutations get selected for and continue to proliferate. This study provides further evidence towards the possibility of homologous mutations evolving in other bacterial species, leading to similar resistances. This study also provides information on how to design the next generation of antibiotics to overcome the mutations effects. 15 
